HLA‐A2‐restricted glypican‐3 peptide‐specific CTL clones induced by peptide vaccine show high avidity and antigen‐specific killing activity against tumor cells
Toshiaki Yoshikawa(Aichi Cancer Center), Tetsuya Nakatsura(Unknown), Shinichi Hayashi(Saitama Cancer Center), Noriko Sakemura(National Cancer Center Hospital East), Shiro Suzuki(National Cancer Center Hospital East), Hirofumi Shirakawa(Shizuoka Cancer Center), Yukië Tanaka(Tokyo Medical and Dental University), Yutaka Motomura(Shizuoka Cancer Center), Munehide Nakatsugawa(Tokyo Medical University Hachioji Medical Center), Daisuke Nobuoka(Fukuyama City Hospital)
Cited by 78
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
|OncoImmunology|2016|178
Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy
|Cell stem cell|2018|163
Risk factors for major morbidity after liver resection for hepatocellular carcinoma
|British journal of surgery|2012|104